Drug intelligence / Profile preview

LTB-SYN

Development stage: Unknown
Lead developer: Universidad Autónoma de San Luis Potosí
Modality: Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Oral

Overview

LTB-SYN is a **recombinant fusion protein antigen** composed of the B subunit of the heat-labile enterotoxin (LTB) from enterotoxigenic Escherichia coli fused to epitopes of α-synuclein. It is produced in genetically modified plant cells (carrot cell line Z4) and is proposed as an oral immunotherapy and vaccine candidate for synucleinopathies such as Parkinson’s disease. The LTB subunit functions as a mucosal adjuvant and facilitates antigen delivery, while the α-synuclein epitopes target immunization against pathological α-synuclein aggregation[3][5][6][7][9].

Other names: LTB-Syn antigenrecombinant LTB-SynLTB-Syn fusion protein

Targets

GM1 (GM1 ganglioside)SNCA (Alpha-synuclein)LTB (Heat-labile enterotoxin B subunit)

Beyond the preview

Go deeper on LTB-SYN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTB-SYN.